Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02023411|
Recruitment Status : Unknown
Verified April 2017 by Ashu Rastogi, Postgraduate Institute of Medical Education and Research.
Recruitment status was: Active, not recruiting
First Posted : December 30, 2013
Last Update Posted : April 6, 2017
Diabetic foot represents a major medical , social and economic problem worldwide.
Charcot's neuroarthropathy, being a common cause of diabetic foot, has been an intriguing topic of research for endocrinologists, podiatrists and surgeons. After its first description by JEAN-MARTIN CHARCOT in 1868, many theories have been put forward regarding its pathophysiology , but not much research has been done for its prevention and treatment , specially the inactive stage.
The course of Charcot 's neuroarthropathy is triphasic , with the diagnosis being usually missed in the active stage, henceforth the patients often come to us with a deformed foot. As a consequence , the osteoclastic activity in active stage renders the foot bones demineralized and weak, thus being susceptible to fracture and fragmentation.
Teriparatide is recombinant human (1-34) parathyroid molecule that has been approved for post-menopausal osteoporosis and in men with primary or secondary osteoporosis. It acts by preferentially stimulating osteoblast over osteoclast activity resulting in new bone formation and an increase in the rate of bone remodeling which manifest as an increase in skeletal mass and bone mineral density .
Keeping the pathophysiology of Charcot's foot in mind, teriparatide may be used as potential treatment for inactive Charcot's neuroarthropathy but there are no studies or randomized trials in this setting, till date. We hypothesize that teriparatide may increase the remodeling of foot bones in Charcot's neuroarthropathy, improve bone mineral density, subsequently leading to a reduction in the risk of fractures and progression of deformities. This study plans to compare the effects of teriparatide in diabetes patients with inactive Charcot's foot in a placebo controlled design.
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Neuropathic Arthropathy||Drug: Teriparatide Other: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus.|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
Active Comparator: teriparatide
10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneously between 8-9 p.m., daily.
recombinant human parathyroid hormone (1-34) subcutaneously every day at 8-9 pm
Placebo Comparator: placebo
10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneously between 8-9 p.m. , daily.
- Remodeling of foot bones [ Time Frame: Two years ]20 diabetic patients , who are Vit.D and calcium sufficient , will be recruited and baseline serum urea, creatinine, calcium, inorganic phosphorus, Alkaline phosphatase, serum 25(OH)- Vit.D, and albumin level will be measured , along with serum iPTH (immunoreactive parathyroid hormone) level. They will undergo baseline X-ray, DEXA (Dual Energy X-Ray Absorptiometry) scan and F18 PET scan of foot with measurement of markers of bone turnover. 10 patients each will receive teriparatide or placebo for 18 months. They will be followed regularly at every 3 months with foot X-ray , serum urea , creatinine, calcium, albumin , inorganic phosphorus and alkaline phosphatase measurement. DEXA scan of foot bones will be done at 12 and 18 months , while F18 PET scan of foot and bone turnover markers will be measured at 3, 12 and 18 months after starting teriparatide therapy. Any side effect will be noted at each visit.
- Clinical events [ Time Frame: Two Years ]
Any of the following will be taken as a secondary end point:
- new onset fracture
- new onset/progression of deformity
- need of amputation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02023411
|Deptt of Endocrinology|
|Chandigarh, India, 160012|
|Chandigarh, India, 160012|
|Principal Investigator:||Anil Bhansali, DM||PGIMER, Chandigarh|